hVIVO plc £6.3m HRV Contract Signed with Biotechnology Client

hVIVO plc (Euronext / LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV – common cold virus) Human Challenge Study Model.

·    Study to enter hVIVO’s state-of-the-art Canary Wharf quarantine facilities in H2 2024

·    Potential to enhance value of the client’s antiviral by generating efficacy data in HRV

The Phase 2a randomised, double-blinded placebo-controlled human challenge trial is planned to take place at the Company’s new specialist state-of-the-art quarantine facilities in Canary Wharf. It will evaluate the effect of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against HRV infection in multiple cohorts of healthy volunteers.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO to hold AGM on 13 May 2024

    hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has confirmed that the Company’s Annual Report and Accounts for the year ended

    hVIVO plc

    Hvivo reports 44% Rise in earnings and Record Year in 2023

    Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation and amortisation (Ebitda) increased to £13m

    hVIVO plc

    hVIVO Investor Conference

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,